Baltimore’s Haystack Oncology, TriSalus Life Sciences to develop liver cancer treatment

Baltimore-based Haystack Oncology, a Quest Diagnostics company and developer of personalized MRD technology, has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus’ SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.